Teva’s Pay-For-Delay Settlement Restricts Brand-Generic Deals

$1.2 billion agreement resolving Provigil litigation with FTC blocks Teva from entering business deal with competitor until 30 days after patent settlement that restricts generic entry, sets $7 million cap on litigation savings.